Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mauna Kea Technologies SAS

This article was originally published in Start Up

Executive Summary

Mauna Kea Technologies is developing Cellvizio, a tiny confocal laser microscopy system small enough to be inserted into the colon, the urinary tract, the lungs, deep in the brain, and other small spaces in the body. Today, every procedure in gastroenterology--a biopsy or a therapeutic intervention-- is already the second, third, or later step in a process that becomes cumbersome simply because clinicians can't get the relevant information from the first step, which is endoscopy. That's where Cellvizio brings advantages, providing a real-time, in vivo microscopic image of tissue to properly characterize it, so a gastroenterologist can both determine and efficiently carry out the proper course of treatment for a particular patient. Cellvizio's most compelling initial applications include the diagnosis of biliary strictures, Barrett's Esophagus, and colonoscopy.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT037615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel